The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal SCCA

ID Number 13-1662

Principal Investigator(s)
Brett A Miles

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate Transoral Robotic Surgery (TORS) alone or combined with either lower dose radiation or lower dose of chemotherapy and radiation in the treatment of early to intermediate stage HPV (Human Papillomavirus) related oropharayngeal cancer.

HPV (Human Papillomavirus) related Oropharyngeal cancer (HPVOPC) accounts for 80% of oropharynx cancer cases in the United States. HPVOPC has better prognosis than patients with oropharyngeal cancer that does not show the HPV virus.  In many hospitals, the standard of care treatment for oropharyngeal cancer is (chemo) radiotherapy.  Even though survival rate has increased because of chemoradiation therapy (CRT), the long-term side effects of radiation therapy are still problematic.  The purpose of this study is to determine whether robotic surgery alone or with reduced doses of radiation or chemoradiotherapy can result in rates of cancer control and survival similar to those that have been previously reported with standard therapy.

Contact Information
(212) 824-7309

Recruiting Patients: Yes